SecProbe.io

CORRESP
1
filename1.htm

  RedHill Biopharma Ltd.

  21 Ha'arba'a Street

   Tel Aviv, 6473921, Israel

  August 15, 2024

  VIA EDGAR

  United States Securities and Exchange Commission

    Division of Corporation Finance

  Office of Life Sciences

  100 F Street N.E.

    Washington, D.C. 20549

  Attention: Chris Edwards

        Re:

          RedHill Biopharma Ltd.

            Registration Statement on Form F-3

  Filed August 9, 2024

  File No. 333-281417 (the “Registration Statement”)

  Ladies and Gentlemen:

  Pursuant to Rule 461 of the General Rules
    and Regulations under the Securities Act of 1933, as amended, RedHill Biopharma Ltd. (the “Company”) hereby respectfully requests
    that the effective date of the Company’s Registration Statement be accelerated by the Securities and Exchange Commission to 4:30 p.m., Eastern Time on August 19,
    2024, or as soon thereafter as practicable.

  The undersigned respectfully requests that it be notified of the effectiveness of the Registration Statement by
    telephone call to the Company’s counsel, Haynes and Boone, LLP, by calling Alla Digilova at (212) 659-4993, and that such effectiveness also be confirmed in writing.

            Very truly yours,

            REDHILL BIOPHARMA LTD.

            By:

            /s/ Dror Ben-Asher

          Dror Ben-Asher

            Chief Executive Officer and Chairman of the
              Board of Directors

          cc:

          Rick A. Werner, Esq., Haynes and Boone, LLP

          Alla Digilova, Esq., Haynes and Boone, LLP